Amgen's Legacy in Cardiovascular Disease Care: From Breakthrough Science to Real-World Impact

Amgen's Repatha, a PCSK9 inhibitor, was developed to help lower LDL-C levels in patients with primary hyperlipidemia, including familial hypercholesterolemia, and reduce the risk of cardiovascular events. Over 57,000 patients have been studied in 51 clinical trials, demonstrating significant LDL-C lowering and cardiovascular risk reduction. Repatha was approved by the US FDA in 2015, providing a new therapeutic option for patients who struggled to reach their LDL-C goals.